InvestorsHub Logo
Followers 91
Posts 11415
Boards Moderated 0
Alias Born 06/06/2014

Re: frrol post# 427896

Sunday, 08/20/2023 9:23:58 AM

Sunday, August 20, 2023 9:23:58 AM

Post# of 466530
Our "precision medicine" approach will likely prove helpful, given that S1 status (wild type vs mutant) is emerging as a primary efficacy factor. Our Partex deal is probably driven by this, where prospective patients would register and get genome screening. Our S1 agonists may prove therapeutic for certain AD, Rett, etc patients, hopefully most.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News